David Shaw’s Cartesian Therapeutics RNAC Stock Holding History

David Shaw’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Buy	+28,651	New	+$212K	﹤0.01%	4415
2021 Q2	–	Sell	-2,379	Closed	-$323K	–	4979
2021 Q1	$323K	Sell	2,379 -4,087	-63%	-$507K	﹤0.01%	3681
2020 Q4	$588K	Buy	+6,466	New	+$561K	﹤0.01%	3312
2020 Q3	–	Sell	-4,196	Closed	-$357K	–	4107
2020 Q2	$357K	Buy	+4,196	New	+$380K	﹤0.01%	3553
2019 Q2	–	Sell	-1,022	Closed	-$73K	–	3831
2019 Q1	$73K	Buy	+1,022	New	+$64.8K	﹤0.01%	3501
2017 Q4	–	Sell	-409	Closed	-$224K	–	3715
2017 Q3	$224K	Buy	+409	New	+$218K	﹤0.01%	3260

Other funds holding RNAC

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

David Shaw's RNAC Position: Q2 2026 in Review

David Shaw opened a new position in Cartesian Therapeutics (RNAC) in Q2 2026: 28,651 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #4415 among its holdings. This is a return to the name: David Shaw previously reported a position in RNAC as recently as Q1 2021.

David Shaw first reported a position in RNAC in Q3 2017 and has held it in 6 quarters since. The position peaked at $588K in Q4 2020. 94 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

David Shaw held 28,651 shares of Cartesian Therapeutics worth $299K as of Q2 2026.
Cartesian Therapeutics was a new David Shaw position in Q2 2026.
Cartesian Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4415 holding.
David Shaw first reported a position in Cartesian Therapeutics in Q3 2017 and has held it in 6 quarters since.
David Shaw's Cartesian Therapeutics position peaked at $588K in Q4 2020.
94 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.